Study Title
An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas
Purpose
To provide access to selumetinib to people with neurofibromatosis type 1 (NF1) with plexiform neurofibromas that cannot be operated on.
Eligibility
Patients ≥ 2 years old with disease before the age of 18 years old
Diagnosis of neurofibromatosis type 1 (NF1)
Plexiform neurofibromas that cannot be surgically completely removed
Study Process
There is no maximum duration for this study as long as it is deemed that a response is being obtained.
Trial Details
Investigator:
IRB:
Quorum
IRB Number:
Trial Type:
NA
Sponsor:
Astra Zenca
Contact Information:
Hematology Oncology Associates
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at (318) 212-8671.